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Abstract Beyond the cardinal motor symptoms, brady-
kinesia, rigidity, tremor and postural instability, defining
the diagnosis of Parkinson’s disease, there is a big spec-
trum of non-motor features that patients may suffer from
and that may reduce their quality of life. Non-motor
symptoms are not only frequent but also often under-
reported by patients and caregivers. As they are frequently
under-recognized by clinicians, they remain consequently
under-treated. This review wants to give a short overview
of the importance of non-motor symptoms on patients’
quality of life and helpful assessment tools that might
facilitate recognition of non-motor features during clinical
setting. Given the wide range of non-motor symptoms in
Parkinson’s disease, we concentrate on common issues
such as depression and sleep disorders like sleep-onset
insomnia or sleep maintenance insomnia and restless legs
syndrome. Thereby, we present some recent studies that
have investigated the efficacy of dopaminergic drugs,
especially dopamine agonists, revealing possible treatment
strategies and thus improving disease management.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
accompanied by both motor and non-motor symptoms (NMS).
Non-motor features can be present at any stage and may
precede the onset of motor signs (Chaudhuri et al. 2005;
Chaudhuri and Naidu 2008). NMS comprise symptoms such as
hyposmia, autonomic dysfunction, gastrointestinal and sen-
sory problems, neuropsychiatric symptoms and sleep disorders
(Sommer et al. 2004; Haehner et al. 2007; Ziemssen and
Reichmann 2007; Chaudhuri and Schapira 2009). The
importance of NMS lies in the fact that they are not only
frequentbut also have a great impact on patients’ quality of life.
Beyond immobility or slowness, non-motor features account
for the most common complaints of PD patients (Lee et al.
2007). Beneath motor fluctuations in advance PD, the most
troublesome problems are ‘non-motor’-like mood changes,
drooling and sleep problems (Politis et al. 2010). From the
patients’ point of view not only the reduction of slowness or
walking difficulties, but also fatigue, contributes to a suc-
cessful treatment outcome (Nisenzon et al. 2011). Concerning
the frequency of NMS, the PRIAMO study revealed that about
98 % of patients suffer from NMS. Thereby symptoms like
apathy, fatigue, psychiatric issuesaswell as deficits in attention
and memory had the most negative impact on quality of life
(Barone et al. 2009). In line with that, several studies revealed
that psychosocial factors like depression accounted signifi-
cantly for quality of life (Global Parkinson’s Disease Survey
Steering Committee 2002; Schrag et al. 2000). Depending on
the study, the mean number of NMS lies between 7 and 12
(Chaudhuri et al. 2006; Martinez-Martin et al. 2007; Barone
et al. 2009). Unfortunately, if not specifically requested, NMS
are often under-reported and poorly recognized thus remaining
under-treated (Chaudhuri et al. 2010).
Recognition and assessment of NMS
Given the frequency as well as the impact of NMS on PD
patients’ quality of life and the consequent implications on
A. Maass (&)  H. Reichmann
Department of Neurology, University Hospital ‘Carl Gustav




J Neural Transm (2013) 120:565–569
DOI 10.1007/s00702-013-0966-4
therapeutic strategies, clinicians need to consider these
issues in their patient interviews. To date, there are some
helpful tools facilitating recognition and assessment of
NMS. For example, NMSQuest is an internationally used
and validated questionnaire enabling rapid screening of
possible non-motor features (Chaudhuri et al. 2006). As
sleep disturbances, among other NMS, have been reported
in 60–90 % and are unrecognized in over 40 % of patients
with PD, clinicians should actively and routinely inquire
about sleep patterns during consultation (Trenkwalder
1998; Korczyn 2006; Chaudhuri et al. 2010). The Parkin-
son Disease Sleep Scale (PDSS) and its revised version
PDSS-2 represent a useful instrument specifically devel-
oped to assess specific aspects of sleep disturbances and
their severity. Problems of sleep in PD consist of sleep
fragmentation with increased periods of wakefulness dur-
ing the night, nocturnal akinesia with or without morning
dystonia, rapid eye movement sleep behaviour disorder
(RBD), restless legs syndrome (RLS), hallucinations and
other neuropsychiatric symptoms, sleep apnea syndromes
and nocturia (Trenkwalder et al. 2011b; Fig. 1). The
revised PDSS-2 meets these nighttime features of PD
patients in large part, reflecting a greater spectrum of
nocturnal problems than the original PDSS. Further, the
PDSS-2 is easy to handle for patient or caregiver and
shows high validity and reliability (Trenkwalder et al.
2011b).
NMS—dopaminergic dysfunction and efficacy
of dopaminergic drugs
Dysfunction of dopaminergic pathways evidently contrib-
utes to a range of non-motor symptoms in PD thus high-
lighting the role of dopaminergic treatments to improve
certain aspects of NMS (Wolters and Braak 2006; Fig. 1).
To date, there are several clinical trials investigating the
efficacy of dopaminergic drugs on key NMS such as
depression, RLS and sleep disturbances.
Depression
Against the background of dopaminergic dysfunction
contributing to the pathophysiology of depression, several
studies highlighted the antidepressant role of dopamine
agonists both in major depression and depression in PD
(Rektorova et al. 2003; Lemke et al. 2006; Dunlop and
Nemeroff, 2007). Comparing pramipexole and pergolide in
PD patients with mild or moderate depression as add-on
therapy to levodopa, both substances showed significantly
reduced depression scores (Rektorova et al. 2003). Raising
the question whether the antidepressant benefit of pram-
ipexole only represented treatment-related motor
improvement, Barone et al. compared pramipexole with
sertraline, a conventional antidepressant, in PD patients
with depression. Depression scores decreased in both
treatment groups, but a significantly greater proportion of
patients recovered under pramipexole compared with ser-
traline (Barone et al. 2006). The antidepressant effects of
pramipexole have further been under-scored in a placebo-
controlled trial. Beck depression inventory (BDI) score as
primary and UPDRS motor score as secondary endpoint
significantly decreased in the pramipexole group. Thereby,
the direct effect of pramipexole on depressive symptoms
accounted for 80 % of total treatment effect thus indicating
a ‘true’ antidepressant effect (Barone et al. 2010). Ropin-
irole, another dopamine agonist, may as well have a mood-
regulating action. The EASE-PD study assessed the anti-
parkinsonian efficacy of prolonged release ropinirole in
advanced cases of PD as adjunct therapy to levodopa.
Compared with placebo, ropinirole showed significant
changes in BDI suggesting an antidepressant action. Nev-
ertheless, confounding effects of motor improvement need
to be considered (Pahwa et al. 2007).
Fig. 1 Different aspects of
sleep disturbances in PD
outlined in the PDSS-2 and their
response to dopaminergic
treatment (modified from
Chaudhuri and Schapira 2009;
Trenkwalder et al. 2011b). PLM
periodic limb movements
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Sleep disorders
With dopamine playing a complex role in the sleep-wake
cycle, some sleep disturbances in PD might be dopamine-
sensitive (Rye and Jankovic 2002). In PD, common sleep
problems are difficulties with falling asleep (sleep-onset
insomnia) and staying in sleep (sleep-maintenance insom-
nia), respectively. Sleep-maintenance insomnia is probably
associated with a range of problems such as nocturnal
akinesia and related motor and non-motor symptoms (e.g.
RLS, RBD, nocturia; Fig. 1) (Lees et al. 1988). There is
evidence that levodopa at bedtime and in a prolonged
release formulation, respectively, lead to an improvement
in sleep quality as well as nocturnal and morning motor
state (Leeman et al. 1987; Van den Kerchove et al. 1993;
Stocchi et al. 1998). The CLEOPATRA-PD study com-
pared the efficacy of oral pramipexole and transdermal
rotigotine in advanced-stage PD with placebo. Both
dopamine agonists showed similar and significant efficacy
in reduction of absolute off-time as primary outcome
measure and significant improvement in secondary efficacy
variables such as the PDSS (Poewe et al. 2007). Similar
results were reported in the EASE-PD study with 24-h
prolonged release ropinirole as adjunct therapy to levodopa
(Pahwa et al. 2007). Specifically focusing on nocturnal
disabilities and early morning akinesia in PD patients, the
recent RECOVER study investigated the effects of trans-
dermal rotigotine. In this multinational, double-blind trial,
287 PD patients were either randomized to receive placebo
(80 completed) or rotigotine (166 completed). Over
1–8 weeks rotigotine was titrated to an optimal dose and
maintained for a 4-week period. Concerning primary out-
come measures, rotigotine lead to significantly greater
improvements in UPDRS Part III scores in early morning
and PDSS-2 total scores. Trenkwalder et al. concluded that
24-h delivery of rotigotine lead to an improvement of sleep
maintenance insomnia by reducing nocturnal PD-specific
symptoms (Trenkwalder et al. 2011a). Another open-label
study, as well investigating the efficacy of transdermal
rotigotine, found an overall improvement in early morning
motor performance, nocturnal akinesia, dystonia, cramps,
nocturia and overall sleep quality (Giladi 2010). In con-
cordance with these findings, several open-label studies
suggested that long-acting dopaminergic agents ameliorate
sleep maintenance in PD patients, e.g. via long-acting ca-
bergoline or continuous jejunal levodopa (Romigi et al.
2006; Honig et al. 2009). Beneath the alleviating effect of
dopamine agonists on some sleep problems in PD, the
clinical practitioner always has to keep in mind increased
daytime sleepiness and sudden onset of sleep as possible
adverse events when using specific dopamine agonists such
as pramipexole or ropinirole (Frucht et al. 1999; Dhawan
et al. 2006; Gjerstad et al. 2006). In case of occurrence,
withdrawal or dose reduction of the dopaminergic agent
needs to be considered.
RBD is a parasomnia characterised by dream-enacting
behaviours related to vivid, usually frightening dreams and
loss of muscle atonia during REM sleep and may predate
the diagnosis of PD. Besides clonazepam as the drug of
choice for RBD (Aurora et al. 2010), melatonin has been
shown to be useful in a small, double-blind, placebo-con-
trolled trial (Kunz and Mahlberg 2010). Pramipexole may
also be considered although there is contradictory evidence
revealing either beneficial or lacking effect on RBD
(Fantini et al. 2003; Kumru et al. 2008). Concerning RLS,
the European RLS Study Group provides a comprehensive
therapeutic algorithm recommending levodopa, dopamine
agonists, gabapentin and other agents depending on the
clinical manifestation and aetiology (Garcia-Borreguero
et al. 2012).
Conclusion
NMS in PD are common and occur across all stages of the
disease. Though representing a key determinant of quality
of life, NMS are often under-reported by patients and
under-recognized by health practitioners consequently
remaining untreated. To overcome this dilemma, helpful
patient-centred questionnaires have been developed alle-
viating the recognition and assessment of NMS, e.g. the
Parkinson Disease Sleep Scale comprising a big spectrum
of nocturnal disturbances in PD. Against the background of
dopaminergic dysfunction accounting for a range NMS,
there is evidence of effective dopaminergic treatment.
Dopamine agonists improve several NMS e.g. reducing
sleep problems and thus potentially improving quality of
life.
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